<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03030170</url>
  </required_header>
  <id_info>
    <org_study_id>35RC15_9846</org_study_id>
    <nct_id>NCT03030170</nct_id>
  </id_info>
  <brief_title>REinforcement of the Pancreas in distaL pAncreatectomY (REPLAY)</brief_title>
  <acronym>REPLAY</acronym>
  <official_title>Does the Strengthening of the Pancreas in Distal Pancreatectomy Using Endo GIA Reload Reinforced Reduce the Occurrence of Pancreatic Fistula? Multicenter Randomized Prospective Open Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Rennes University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Rennes University Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Despite an improvement regarding morbidity and mortality since 30 years, especially in expert&#xD;
      centers, pancreatic surgery remains currently associated to a significant postoperative&#xD;
      morbidity reaching more than 60%. Regarding distal pancreatectomy (DP), the main complication&#xD;
      following surgery is the occurrence of postoperative pancreatic fistula (PF) which may be&#xD;
      able to lead an increased risk of bleeding, gastroparesis and finally a longer hospital&#xD;
      stays. The main risk factors associated to the occurrence of pancreatic fistula are&#xD;
      represented by the texture of the pancreatic parenchyma (soft pancreas) and the caliber of&#xD;
      the main pancreatic duct (&lt;3mm). Looking for new means of reducing the occurrence of&#xD;
      pancreatic fistula is a priority in pancreatic surgery and a genuine public health issue.&#xD;
      Currently, no formal recommendations concerning the optimal technical for closure of the&#xD;
      distal stump in DP are available. In fact, manual closing by elective suturing or stapling of&#xD;
      the main pancreatic duct give similar results. The use of a reinforcing stapling potentially&#xD;
      represents a simple way to decrease the occurrence of pancreatic fistula and requires&#xD;
      evaluation by a prospective randomized study.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">June 28, 2017</start_date>
  <completion_date type="Anticipated">April 30, 2021</completion_date>
  <primary_completion_date type="Actual">December 14, 2020</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>intervention with reinforced medical device, or not</intervention_model_description>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Rate of postoperative pancreatic fistula defined by the criteria of the ISGPF</measure>
    <time_frame>up to 90 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Gravity of the pancreatic fistula according to the 3 stages of ISGPF</measure>
    <time_frame>up to 90 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of the occurrence of gastroparesis and its severity according to the criteria of ISGPS</measure>
    <time_frame>up to 90 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of the occurrence of postoperative haemorrhage</measure>
    <time_frame>up to 90 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Length of hospital stay</measure>
    <time_frame>up to 90 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Perioperative mortality and 90-day mortality</measure>
    <time_frame>up to 90 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall morbidity classified and categorized according to the classification of Dindo and Clavien</measure>
    <time_frame>until 90 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rehospitalization rates</measure>
    <time_frame>until 90 days</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">207</enrollment>
  <condition>Distal Pancreatectomy (DP)</condition>
  <arm_group>
    <arm_group_label>Experimental</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Stapling of the pancreas with ENDO GIA Reinforced reload</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Stapling of the pancreas with ENDO GIA X-tra Thick reload</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>ENDO GIA X-tra Thick reload with Tri Staple Technology</intervention_name>
    <description>Suture of the pancreas by normal stapling</description>
    <arm_group_label>Control</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>ENDO GIA Articulating Reinforced Reload with Tri-Staple Technology</intervention_name>
    <description>Suture of the pancreas by reinforced stapling</description>
    <arm_group_label>Experimental</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  All patients who undergo DP whether made by open or laparoscopic surgery&#xD;
&#xD;
          -  Patients 18 years of age or older,&#xD;
&#xD;
          -  Benefiting from a social security scheme,&#xD;
&#xD;
          -  Having given his free, informed and written consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  History of pancreatic abdominal surgery&#xD;
&#xD;
          -  Severe co-morbidity type renal failure requiring hemodialysis, unbalanced diabetes,&#xD;
             major respiratory insufficiency, heart failure ≥ stage 3 NYHA;&#xD;
&#xD;
          -  Persons of full age who are subject to legal protection, persons deprived of liberty.&#xD;
&#xD;
          -  Pregnant or nursing women&#xD;
&#xD;
          -  Patients participating in or participating in another study&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>LAURENT SULPICE, MD/PHD</last_name>
    <role>Principal Investigator</role>
    <affiliation>RENNES PONTCHAILLOU HOSPITAL</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Service de chirurgie Hépato-pancréato-biliaire</name>
      <address>
        <city>Clichy</city>
        <zip>92110</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Service de chirurgie générale, digestive et de la transplantation hépatique</name>
      <address>
        <city>Lyon</city>
        <zip>69317</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AP-HM - Institut Paoli Calmettes_ service de chirurgie oncologique digestive</name>
      <address>
        <city>Marseille</city>
        <zip>13009</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Service de chirurgie digestive et endocrienne</name>
      <address>
        <city>Nantes</city>
        <zip>44093</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut Mutualiste Montsouris</name>
      <address>
        <city>Paris 14</city>
        <zip>75674</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Universitaire Rennes Pontchaillou</name>
      <address>
        <city>Rennes</city>
        <zip>35000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Unité d'hospitalisation Chirurgie hépatique, biliaire et pancréatique</name>
      <address>
        <city>Villejuif</city>
        <zip>94800</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>January 16, 2017</study_first_submitted>
  <study_first_submitted_qc>January 23, 2017</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 24, 2017</study_first_posted>
  <last_update_submitted>April 13, 2021</last_update_submitted>
  <last_update_submitted_qc>April 13, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 14, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

